Organoids and Organ-on-a-Chip Technologies in Modern Medical Research: Advances, Applications, Challenges and Future Prospects

Hannah Whitmore
Centre for Digital Innovation, Kingswell University, United Kingdom

Received : 05/05/2026 ; Accepted : 29/08/2026 ; Published : 01/09/2026

Abstract
Organoids and organ-on-a-chip technologies have emerged as transformative platforms in modern biomedical research, offering new approaches for studying human biology, disease mechanisms, drug development, toxicity assessment, and personalized medicine. Conventional experimental systems, including two-dimensional cell cultures and animal models, have generated substantial scientific knowledge but often fail to reproduce the structural, cellular, mechanical, and biochemical complexity of human tissues and organs. Organoids are three-dimensional, self-organizing cellular structures that reproduce selected architectural and functional characteristics of organs. Organ-on-a-chip systems, in contrast, use microengineering and microfluidics to recreate aspects of human tissue physiology within controlled miniature platforms. Both technologies seek to bridge the gap between simplified laboratory models and human biological systems. This research paper examines the scientific foundations of organoids and organ-on-a-chip technologies and evaluates their applications in cancer research, infectious diseases, drug discovery, pharmacology, toxicology, regenerative medicine, and precision medicine. Particular attention is given to patient-derived organoids, multi-organ chips, microfluidic systems, vascularization, mechanical stimulation, and the integration of artificial intelligence. The paper also explores the complementary relationship between organoids and organ-on-a-chip platforms. While organoids provide complex three-dimensional cellular organization, organ-on-a-chip technologies offer precise control of fluid flow, mechanical forces, oxygen gradients, and tissue interfaces. Their integration may create increasingly sophisticated human-relevant models. Nevertheless, limitations remain, including incomplete maturation, lack of full physiological complexity, reproducibility problems, vascular and immune-system limitations, technical standardization, manufacturing costs, and regulatory uncertainty. Future developments are expected to integrate stem-cell biology, tissue engineering, microfluidics, artificial intelligence, single-cell sequencing, spatial biology, and personalized medicine. The convergence of these technologies could substantially improve the prediction of human responses to diseases and therapeutics while reducing dependence on traditional experimental models.

Keywords: Organoids, Organ-on-a-Chip, Microfluidics, Tissue Engineering, Stem Cells, Three-Dimensional Cell Culture, Drug Discovery, Toxicology, Disease Modelling, Precision Medicine, Personalized Medicine, Biomedical Research

1. Introduction

Biomedical research has traditionally relied on a combination of laboratory cell cultures and animal models to understand disease mechanisms and evaluate potential treatments. These approaches remain indispensable, but both have important limitations.

Conventional two-dimensional cell cultures generally grow cells on flat surfaces. Although useful for basic cellular experiments, they often fail to reproduce the three-dimensional architecture, cell-cell interactions, extracellular matrix, mechanical forces, and chemical gradients present in living tissues.

Animal models provide greater biological complexity but may not always accurately reproduce human-specific physiology or disease mechanisms.

These limitations have stimulated the development of advanced human-relevant experimental models.

Two particularly important technologies are:

Organoids and **organ-on-a-chip systems**.

Organoids are three-dimensional cellular structures generated from stem cells or tissue-derived cells that can self-organize into structures resembling aspects of particular organs.

Organ-on-a-chip technologies use microfabrication, microfluidics, biomaterials, and living cells to reproduce selected physiological functions of human organs on miniature devices.

The conceptual difference can be expressed as:

$$
[
\text{Organoid}
\rightarrow
\text{Biological Self-Organization}
]
$$

whereas:

$$
[
\text{Organ-on-a-Chip}
\rightarrow
\text{Engineering-Controlled Physiology}.
]
$$

Increasingly, researchers are combining these approaches:

$$
\boxed{
\textbf{Organoids}
+
\textbf{Microfluidics}
+
\textbf{Biomaterials}
+
\textbf{Stem Cells}
\text{Advanced Human Tissue Models}
}
$$

The potential applications extend across cancer research, infectious disease, drug discovery, toxicology, regenerative medicine, developmental biology, and personalized medicine.

---

2. Concept of Organoids

Organoids are three-dimensional structures that reproduce selected structural and functional characteristics of organs.

They can be generated from:

- Embryonic stem cells
- Induced pluripotent stem cells
- Adult stem/progenitor cells
- Patient-derived tissue

Organoid formation generally depends on carefully controlled signaling environments that encourage cells to proliferate, differentiate, and self-organize.

A simplified pathway is:

[
\text{Stem Cell}
\rightarrow
\text{Differentiation}
\rightarrow
\text{Self-Organization}
\rightarrow
\text{Organoid}.
]

Organoids do not represent complete miniature organs. Instead, they reproduce selected characteristics of tissues.

This distinction is scientifically important.

---

3. Development of Organoid Technology

The development of organoid research has been closely connected with advances in stem-cell biology.

The discovery that pluripotent stem cells can differentiate into multiple tissue types provided an important foundation for three-dimensional models.

Adult stem-cell-derived organoids subsequently demonstrated that tissue-specific progenitor cells could generate complex structures resembling their tissues of origin.

Important organoid systems include:

- Intestinal organoids
- Brain organoids
- Liver organoids
- Kidney organoids
- Lung organoids
- Pancreatic organoids
- Retinal organoids
- Gastric organoids

- Prostate organoids
- Tumor organoids

These models have substantially expanded experimental possibilities.

---

4. Types of Organoids

4.1 Intestinal Organoids

Intestinal organoids reproduce several features of intestinal epithelium.
They can contain different cell populations, including:

- Absorptive cells
- Secretory cells
- Goblet cells
- Stem/progenitor cells

They have applications in studying:

- Intestinal development
- Inflammatory diseases
- Infectious diseases
- Drug absorption
- Cancer

---

5. Brain Organoids

Brain organoids are three-dimensional neural structures generated primarily from pluripotent stem cells.
They can reproduce selected aspects of:

- Neural development
- Neuronal differentiation
- Brain organization

Brain organoids have been investigated for:

- Neurodevelopmental disorders
- Neurological diseases
- Viral infections
- Brain tumors
- Drug testing

However, they do not fully reproduce the mature human brain.
Major limitations include incomplete vascularization, limited maturation, and restricted representation of immune and systemic interactions.

---

6. Liver Organoids

Liver organoids can reproduce selected features of hepatic tissue.
They have applications in:

- Liver disease research
- Drug metabolism
- Hepatotoxicity testing
- Regenerative medicine

- Genetic disease modelling

Because the liver plays a central role in drug metabolism, liver organoids may become increasingly important in pharmacological research.

---

7. Kidney Organoids

Kidney organoids can reproduce aspects of renal development and nephron formation.

Potential applications include:

- Kidney development
- Genetic kidney disease
- Drug toxicity
- Regenerative medicine

However, achieving mature, fully functional kidney structures with appropriate vascular and filtration systems remains challenging.

---

8. Lung Organoids

Lung organoids provide models for studying:

- Lung development
- Respiratory infections
- Pulmonary disease
- Fibrosis
- Cancer

They have become particularly valuable for studying interactions between respiratory tissues and infectious agents.

---

9. Tumor Organoids

Cancer-derived organoids are particularly promising for precision oncology.

Tumor tissue obtained from a patient can potentially be cultured into a three-dimensional tumor model.

The concept is:

[
\text{Patient Tumor}
\rightarrow
\text{Tumor Organoid}
\rightarrow
\text{Drug Testing}
\rightarrow
\text{Treatment Selection}.
]

This approach may enable researchers to test multiple therapeutic options against patient-specific tumor tissue.

---

10. Patient-Derived Organoids

Patient-derived organoids are an important component of personalized medicine.

They can preserve selected characteristics of the original tumor or tissue.
Potential applications include:

- Drug sensitivity testing
- Disease modelling
- Treatment resistance studies
- Biomarker discovery
- Personalized therapy development

However, organoid behavior does not always perfectly reproduce the original disease environment.

---

11. Concept of Organ-on-a-Chip

Organ-on-a-chip technologies are miniature platforms that combine living cells with engineering systems to reproduce selected functions of human organs.
They commonly incorporate:

- Microfluidic channels
- Living cells
- Biomaterials
- Sensors
- Controlled fluid flow
- Mechanical stimulation

A simplified system can be represented as:

$$
[
\text{Cells}
+
\text{Microfluidics}
+
\text{Mechanical Signals}
+
\text{Biochemical Environment}
\rightarrow
\text{Organ-on-a-Chip}.
]
$$

The objective is not necessarily to reproduce an entire organ but to recreate specific physiological functions.

---

12. Microfluidics

Microfluidics is fundamental to many organ-on-a-chip platforms.
It enables precise control of fluids at microscopic scales.
Researchers can manipulate:

- Nutrient delivery
- Oxygen levels
- Chemical gradients
- Drug concentrations

- Fluid shear stress

This allows experimental conditions to be controlled more precisely than in conventional culture systems.

---

13. Organ-on-a-Chip Systems

Several organ-specific systems have been developed.

Examples include:

- Lung-on-a-chip
- Heart-on-a-chip
- Liver-on-a-chip
- Kidney-on-a-chip
- Brain-on-a-chip
- Gut-on-a-chip
- Blood-brain-barrier-on-a-chip
- Bone-marrow-on-a-chip

Each system seeks to reproduce selected physiological processes.

---

14. Lung-on-a-Chip

The lung is an important target because normal pulmonary function depends on interactions between epithelial and vascular tissues and mechanical breathing forces.

Lung-on-a-chip systems can incorporate:

[
\text{Airway/Alveolar Cells}
+
\text{Endothelial Cells}
+
\text{Fluid Flow}
+
\text{Mechanical Stretch}.
]

These systems can be used to study:

- Respiratory infections
- Inflammation
- Pulmonary toxicity
- Drug delivery
- Lung injury

---

15. Gut-on-a-Chip

The gastrointestinal tract experiences continuous mechanical and chemical stimulation.

Gut-on-a-chip models can incorporate:

- Intestinal epithelial cells
- Fluid flow
- Mechanical deformation

- Microbial interactions

This enables investigation of:

- Nutrient absorption
- Drug transport
- Intestinal inflammation
- Host-microbiome interactions

The integration of gut organoids with microfluidic systems may produce increasingly realistic intestinal models.

---

16. Liver-on-a-Chip

The liver plays an important role in metabolism and detoxification.

Liver-on-a-chip systems can therefore be used for:

- Drug metabolism
- Toxicity testing
- Liver disease research
- Pharmaceutical development

A major advantage is the ability to expose liver cells to controlled drug concentrations under dynamic flow conditions.

---

17. Kidney-on-a-Chip

Kidney-on-a-chip models seek to reproduce selected functions of renal tissue.

Potential applications include:

- Drug nephrotoxicity
- Filtration studies
- Kidney disease modelling
- Transport mechanisms

These systems may provide useful alternatives or complements to conventional models.

---

18. Heart-on-a-Chip

Heart-on-a-chip systems use cardiac cells to reproduce aspects of cardiac physiology.

They can investigate:

- Cardiac contraction
- Electrical activity
- Drug-induced toxicity
- Cardiovascular disease

A major advantage is the ability to observe functional responses to therapeutic compounds.

---

19. Blood-Brain-Barrier-on-a-Chip

The blood-brain barrier presents a major challenge for drug delivery to the central nervous system.

Organ-on-a-chip platforms can model interactions between:

- Brain endothelial cells
- Supporting cells

- Neural tissues
- Fluid environments

These models may help researchers investigate drug transport across the blood-brain barrier.

---

20. Multi-Organ-on-a-Chip Systems

Human physiology is not divided into isolated organs.

Drugs absorbed through the intestine may be metabolized by the liver and subsequently affect the heart or brain.

This has encouraged the development of interconnected multi-organ systems.

A simplified model is:

[
\text{Gut}
\rightarrow
\text{Liver}
\rightarrow
\text{Circulation}
\rightarrow
\text{Target Organ}.
]

Multi-organ chips attempt to reproduce such interactions.

---

21. Organoid-on-a-Chip Technology

One of the most promising developments is the combination of organoids with microfluidic systems.

Organoids provide:

- Cellular diversity
- Three-dimensional organization
- Developmental characteristics

Organ-on-a-chip systems provide:

- Fluid control
- Mechanical forces
- Nutrient delivery
- Waste removal
- Controlled microenvironments

Together:

[
\boxed{
\text{Organoid}
+
\text{Organ-on-a-Chip}
\text{Enhanced Physiological Model}
}
]

This integrated approach may overcome some limitations of each technology individually.

---

22. Applications in Drug Discovery

Drug development is expensive and time-consuming.

Many compounds fail during clinical development because laboratory models do not adequately predict human responses.

Organoids and organ-on-a-chip technologies may improve drug screening by providing more human-relevant systems.

The potential workflow is:

[
\text{Drug Candidate}
\rightarrow
\text{Organoid/Chip Testing}
\rightarrow
\text{Efficacy}
+
\text{Toxicity}
\rightarrow
\text{Candidate Selection}.
]

---

23. Toxicology

Drug toxicity is one of the major reasons for failure during pharmaceutical development.

Organ-specific chips can test whether compounds affect:

- Liver
- Heart
- Kidney
- Brain
- Lung

This may enable earlier identification of potentially toxic compounds.

---

24. Infectious Disease Research

Organoids provide powerful models for studying host-pathogen interactions.

Researchers can use organoids to investigate:

- Viral infections
- Bacterial infections
- Parasites
- Host immune responses

Organ-on-a-chip systems can add controlled physiological conditions.

For example:

[
\text{Human Tissue Model}
+

\text{Pathogen}
+
\text{Controlled Environment}
\rightarrow
\text{Disease Model}.
]

---

25. Cancer Research

Cancer organoids provide opportunities to study tumor biology in three dimensions.
They can be used to investigate:

- Tumor growth
- Metastasis
- Drug resistance
- Cancer stem cells
- Tumor heterogeneity

Patient-derived cancer organoids may also contribute to individualized treatment research.

---

26. Regenerative Medicine

Organoids can serve as models for understanding how tissues develop.
They may also provide starting points for future regenerative applications.
Potential approaches include:
[
\text{Stem Cells}
\rightarrow
\text{Organoid}
\rightarrow
\text{Tissue Engineering}
\rightarrow
\text{Regenerative Therapy}.
]
However, transplanting organoids safely and achieving complete functional integration remains an active area of research.

---

27. Developmental Biology

Organoids provide a unique window into human development.
Researchers can observe cellular differentiation and tissue organization under controlled laboratory conditions.
This can help investigate:

- Early development
- Congenital disorders
- Tissue patterning
- Developmental signaling

Human organoids may therefore provide information that is difficult to obtain directly from human embryos or tissues.

---

28. Personalized Medicine

Personalized medicine is one of the most important long-term applications.
Patient-derived cells can potentially be used to create disease-specific models.
The process can be represented as:

[
\text{Patient}
\rightarrow
\text{Cell Collection}
\rightarrow
\text{Organoid}
\rightarrow
\text{Drug Screening}
\rightarrow
\text{Personalized Treatment}.
]

This could be particularly valuable for cancers and rare diseases.

---

29. Artificial Intelligence and Organoid Research

Artificial intelligence can improve the analysis of complex organoid experiments.
AI can analyze:

- Cell morphology
- Growth patterns
- Differentiation
- Drug responses
- Organoid viability

A simplified workflow is:

[
\text{Organoid Images}
\rightarrow
\text{AI Analysis}
\rightarrow
\text{Phenotype Classification}
\rightarrow
\text{Treatment Prediction}.
]

AI may also assist in optimizing organoid culture conditions.

---

30. Single-Cell and Spatial Technologies

Modern organoid research increasingly incorporates advanced molecular techniques.
Single-cell sequencing can identify individual cellular populations.

Spatial technologies can reveal where different cells and molecules are located.
Together:

$$[\text{Single-Cell Data} + \text{Spatial Data} \rightarrow \text{High-Resolution Tissue Characterization}.]$$

This can help researchers determine how closely organoids resemble human tissues.

---

31. Advantages of Organoids

Major advantages include:

- Three-dimensional architecture
- Human cellular systems
- Cellular diversity
- Disease-specific modelling
- Patient-derived models
- Long-term experimental potential
- Compatibility with molecular analysis

Organoids can therefore provide biological complexity beyond conventional 2D cultures.

---

32. Limitations of Organoids

Despite their promise, organoids have important limitations.
They may lack:

- Complete vascular systems
- Mature immune components
- Full physiological architecture
- Systemic circulation
- Normal mechanical forces
- Complete organ-level interactions

Consequently:

$$[\text{Organoid} \neq \text{Complete Human Organ}.]$$

This distinction should remain central when interpreting experimental findings.

---

33. Advantages of Organ-on-a-Chip

Organ-on-a-chip technologies provide:

- Precise environmental control
- Fluid flow

- Mechanical stimulation
- Controlled chemical gradients
- Real-time monitoring
- Possibility of interconnected organ models

They can reproduce certain physiological conditions that conventional cultures cannot.

---

34. Limitations of Organ-on-a-Chip

Challenges include:

- Complex device fabrication
- High technical expertise
- Standardization
- Reproducibility
- Scaling
- Cell sourcing
- Long-term stability
- Lack of complete systemic physiology

The technology must become more standardized before widespread adoption.

---

35. Comparison of Traditional Models, Organoids and Organ-on-a-Chip

Feature	2D Cell Culture	Animal Models	Organoids	Organ-on-a-Chip
3D structure	Low	High	High	Variable
Human cells	Often	Usually no	Yes	Yes
Physiological flow	Low	High	Limited	High
Patient-specific models	Possible	Limited	Strong potential	Strong potential
Mechanical control	Low	Natural	Limited	High
Molecular analysis	High	High	High	High
Multi-organ interaction	Very limited	High	Limited	Increasing
Experimental control	High	Moderate	High	Very high

No single platform is universally superior. Their value depends on the scientific question.

---

36. Ethical Considerations

Organoid technologies also create ethical questions.

Brain organoids are particularly important because increasingly sophisticated models may develop features associated with neural activity.

Questions include:

- Could increasingly complex brain organoids acquire morally relevant properties?
- How should donor-derived tissues be governed?
- What consent is required for future uses?
- Who owns patient-derived organoid models?

Although many of these questions remain theoretical, continued technological development makes ethical discussion increasingly important.

---

37. Regulatory Considerations

For organoids and organ-on-a-chip technologies to influence clinical practice, regulators need reliable standards.

Important areas include:

- Reproducibility
- Quality control
- Validation
- Manufacturing
- Data interpretation
- Clinical relevance

A critical question is:

[
\text{Does the Model Predict Human Outcomes?}
]

Demonstrating predictive validity will be essential.

---

38. Commercialization and Standardization

The transition from research laboratories to industrial and clinical applications requires standardization.

Commercial platforms need:

- Reproducible protocols
- Defined materials
- Reliable cell sources
- Quality-control standards
- Automated workflows

Automation may eventually allow large-scale screening using standardized organoid and chip systems.

---

39. Future Prospects

Future organoid and organ-on-a-chip technologies are likely to become increasingly integrated.

A future platform could contain:

[
\boxed{
\text{Patient-Derived iPSC}
+
\text{Organoid}
+
\text{Microfluidic Chip}
+
\text{Immune Cells}

+
\text{Vascular System}
+
\text{AI}
}
]
Such systems could provide highly personalized experimental environments.

---

40. Digital Twins and Personalized Medicine

One ambitious future direction is the development of biological or medical "digital twins." Patient information could be integrated with laboratory models:

[
\text{Patient Data}
+
\text{Organoid}
+
\text{Organ-on-a-Chip}
+
\text{AI}
\rightarrow
\text{Predictive Patient Model}.
]

Such systems could potentially simulate treatment responses before therapies are administered. Although this remains an emerging concept, it illustrates the convergence of biological and computational medicine.

---

41. Future of Drug Development

Organoid and organ-on-a-chip technologies may contribute to a more efficient pharmaceutical development pipeline.

The future workflow could become:

[
\text{Target Identification}
\rightarrow
\text{Organoid Screening}
\rightarrow
\text{Multi-Organ Toxicity Testing}
\rightarrow
\text{Candidate Selection}
\rightarrow
\text{Clinical Trials}.
]

This could potentially reduce the number of ineffective compounds entering expensive later-stage development.

42. Conclusion

Organoids and organ-on-a-chip technologies represent two of the most promising developments in modern biomedical research. Both technologies seek to address important limitations of traditional experimental systems by creating more sophisticated and human-relevant models.

Organoids reproduce selected characteristics of human tissues through three-dimensional cellular organization and self-assembly. Organ-on-a-chip technologies complement this biological complexity with engineered control over fluid flow, mechanical forces, biochemical conditions, and tissue interfaces.

Their applications extend across:

- Disease modelling
- Cancer research
- Drug discovery
- Toxicology
- Infectious disease
- Regenerative medicine
- Developmental biology
- Precision medicine

The combination of these technologies is particularly promising. Organoid-on-a-chip systems may provide greater biological realism while retaining the experimental control associated with microfluidics.

Nevertheless, significant challenges remain. Organoids may not reproduce complete organ physiology, while organ-on-a-chip systems can be technically complex and difficult to standardize. Questions concerning vascularization, immune interactions, maturation, reproducibility, scalability, validation, and regulatory acceptance must be addressed.

The future is likely to involve convergence among:

```
[
\boxed{
\text{Stem                                                    Cells}
+
\text{Organoids}
+
\text{Microfluidics}
+
\text{Organ-on-a-Chip}
+
\text{AI}
+
\text{Multi-Omics}
}
]
```

Such integration could create increasingly predictive models of human biology and disease. Ultimately, these technologies may contribute to a new generation of biomedical research in which experimental systems become more personalized, physiologically relevant, and capable of predicting individual responses to disease and therapy.

References

1. Clevers, H. (2016). Modeling development and disease with organoids. *Cell, 165*(7), 1586–1597.
2. Drost, J., & Clevers, H. (2018). Organoids in cancer research. *Nature Reviews Cancer, 18*, 407–418.
3. Fatehullah, A., Tan, S. H., & Barker, N. (2016). Organoids as an in vitro model of human development and disease. *Nature Cell Biology, 18*, 246–254.
4. Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010). Reconstituting organ-level lung functions on a chip. *Science, 328*(5986), 1662–1668.
5. Ingber, D. E. (2020). Human organs-on-chips for disease modelling, drug development and personalized medicine. *Nature Reviews Genetics, 21*, 467–491.
6. Lancaster, M. A., & Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science, 345*(6194), 1247125.
7. Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., et al. (2013). Cerebral organoids model human brain development and microcephaly. *Nature, 501*, 373–379.
8. Leslie, M. (2015). Cell biology: Tissues on a chip. *Science, 347*(6223), 474–476.
9. Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021). Organs-on-chips: Into the next decade. *Nature Reviews Drug Discovery, 20*, 345–361.
10. Miller, P. G., & Shuler, M. L. (2016). Design and demonstration of a multi-tissue system for studying drug metabolism and pharmacokinetics. *Biotechnology and Bioengineering, 113*, 777–787.
11. Paşca, A. M., Sloan, S. A., Clarke, L. E., Tian, Y., Makinson, C. D., Huber, N., et al. (2015). Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. *Nature Methods, 12*, 671–678.
12. Ronaldson-Bouchard, K., Ma, S. P., Yeager, K., Chen, T., Song, L., Sirabella, D., et al. (2018). Advanced maturation of human cardiac tissue grown from pluripotent stem cells. *Nature, 556*, 239–243.
13. Shamir, E. R., & Ewald, A. J. (2014). Three-dimensional organotypic culture: Experimental models of mammalian biology and disease. *Nature Reviews Molecular Cell Biology, 15*, 647–664.
14. Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019). Modelling cancer in microfluidic human organs-on-chips. *Nature Reviews Cancer, 19*, 65–81.
15. Takebe, T., Sekine, K., Enomura, M., Takehiro, H., Koike, H., Kimura, M., et al. (2013). Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature, 499*, 481–484.

16. Trapecar, M., Wogram, E., Svoboda, D., Communal, C., O'Rourke, B., & Jeong, J. (2021). Multi-organ-on-chip systems for drug development and disease modelling. *Nature Reviews Drug Discovery*.
17. van der Meer, A. D., & van den Berg, A. (2012). Organs-on-chips: Breaking the in vitro impasse. *Integrative Biology, 4*, 461–470.
18. Velasco, S., Kedaigle, A. J., Simmons, S. K., Nash, A., Rocha, M., Quadrato, G., et al. (2019). Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. *Nature, 570*, 523–527.
19. Yin, X., Li, Y., et al. (2019). Engineering organoids and organ-on-chip systems for human disease modelling. *Nature Reviews Materials*.
20. Zhu, Y., Yin, F., Wang, H., et al. (2021). Organoid and organ-on-a-chip technologies in drug discovery and personalized medicine. *Advanced Drug Delivery Reviews*.